Skip to main content
TipRanks
Go Ultimate75% OFF

Inventiva (6IV) Q2 2026 Earnings Report

1 Followers

DE:6IV Q2 2026 EPS Results

Actual EPS
-EUR 0.18
Consensus EPS
-EUR 0.33
Beat/Miss
Beat by +EUR 0.16
One Year Ago EPS
-EUR 1.38

DE:6IV Q2 2026 Revenue Results

Actual Revenue
EUR 20.00K
Expected Revenue
EUR 5.55M
Beat/Miss
Missed by -EUR 5.53M
YoY Revenue Growth
-99.55%

Earnings Announcement Details

Quarter
Q2 2026
Date
09/28/2026
Time
Before Open
Conference Call
Monday, September 28, 2026
DE:6IV Upcoming Earnings

Inventiva's next earnings date is estimated for March 31, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Sep 28, 2026|% Change Since:-0.86%|
Earnings Call Sentiment|Positive

The call was strongly focused on positive clinical, regulatory, commercial, and financing progress: NATiV3 is fully recruited with the final 72-week visit completed, phase II-B results were described as robust, the balance sheet was strengthened, and cash runway covers the expected Q4 2026 readout and potential 2027 filing. The principal negatives were the pending phase III outcome, known weight gain and edema effects, lower-end liver stiffness results, increased marketing and G&A expenses, and financing runway beyond Q2 2027 remaining conditional. Highlights significantly outweighed the stated challenges.

Company Guidance

Inventiva remains on track to report NATiV3 top-line data in the fourth quarter of 2026 from the main cohort of 1,009 participants, is preparing for a potential NDA submission with the FDA in the first half of 2027, and is building for a potential commercial launch in 2028; the market potential is expected to exceed $15 billion by 2035. Current financing assumptions, existing resources, and completed financing transactions provide cash runway until the end of the second quarter of 2027, while, assuming full exercise of Tranche 3 warrants on the back of a positive top-line result and successful completion of Tranche C of the debt financing transaction, cash runway would extend to the start of the first quarter of 2028. The company secured new debt financing of up to EUR 130 million in three committed tranches, subject to conditions, with an initial drawdown of two tranches of EUR 75 million gross, plus an additional uncommitted tranche of up to EUR 20 million, and completed an underwritten public offering generating gross proceeds of EUR 103 million; it is not guiding on any future raises, top-line data contents, or what it expects over time for edema.

  • NATiV3 Phase III Trial Remains on TrackInventiva remains on track to report top-line results from the NATiV3 phase III MASH trial in the fourth quarter of 2026. The last patient completed the final 72-week visit earlier in September, and the main cohort enrolled 1,009 participants with biopsy-confirmed non-cirrhotic MASH and F2 or F3 fibrosis.
  • Positive Phase II-B Histology ResultsIn the six-month NATIVE phase II-B study, lanifibranor delivered an 18% placebo-adjusted improvement in fibrosis, a 26% improvement on MASH resolution, and a 24% improvement on the composite endpoint.
  • Robust Results Across Disease StagesAfter excluding patients with earlier-stage F1 disease, Inventiva said lanifibranor continued to show robust effects across all three histologic endpoints, indicating that the drug worked equally well in early and later-stage disease. In the type 2 diabetes subgroup, treated patients were roughly eight times more likely than placebo patients to achieve dual histologic improvement.
  • Differentiated Once-Daily Oral MechanismLanifibranor is designed to address both intrahepatic and extrahepatic disease processes through once-daily oral modulation of all three PPAR isoforms: alpha, delta, and gamma. The company described the molecule as structurally and mechanistically distinct from fibrates and thiazolidinediones, with partial PPAR gamma agonism.
  • Regulatory Readiness for 2027 FilingInventiva is preparing for a potential NDA submission to the FDA in the first half of 2027. Subject to positive phase III results, the company intends to seek accelerated approval with the FDA and conditional approval with the EMA.
  • Commercial Organization Being BuiltThe company is building a commercial organization with the experience and capabilities needed to support a potential U.S. commercial launch in 2028, if lanifibranor is approved.
  • Large and Growing MASH OpportunityInventiva cited an estimated 18 million Americans living with MASH, with only 10% currently diagnosed. Diagnosis has increased approximately 25% versus 2024, and approximately 374,000 patients with F2 or F3 disease are already in treatment or under physician care. The company cited market potential expected to exceed $15 billion by 2035.
  • NATiV3 Designed for Conservative Phase III ValidationNATiV3 includes approximately 1,400 patients across two cohorts: a 1,009-patient placebo-controlled randomized main cohort with F2 or F3 disease and an exploratory cohort of 410 patients, predominantly with F1 or F4 disease. The primary endpoint is powered at 90% using assumptions of a higher placebo response and lower treatment effect than observed in phase II-B.
  • Contemporary Patient Population and Background Therapy AnalysisThe NATiV3 population has higher diabetes prevalence, more advanced fibrosis, and greater use of GLP-1s and SGLT2 inhibitors than the phase II-B population. Approximately 9% of patients received GLP-1 drop-ins at non-MASH doses, and the company has pre-specified sensitivity analyses for the potential impact of GLP-1 and SGLT2 use.
  • Weight Gain Profile Characterized as ManageableIn the completed NATIVE trial, approximately half of patients had no weight gain defined as anything beyond plus or minus 5%. Among patients who did have weight gain, only about 10% of adverse-event reports related to weight gain, and weight gain was not a primary driver of treatment discontinuations. In a separate 48-week scleroderma study, weight gain appeared to plateau around weeks 24 to 30 and remained stable through week 48.
  • Lower Edema Prevalence Than PioglitazoneIn NATIVE II-B, unadjusted edema prevalence ranged from 7% to 10% across the two doses, while drug-related edema was approximately 2%. The company contrasted this with an estimated 20% to 25% edema range for pioglitazone in a similar MASH population. Reported edema events were generally mild to moderate and were not primary drivers of discontinuation.
  • Potential Mitigation With SGLT2 InhibitorsBased on the LEGEND study, the company said gamma-related effects, including weight gain and edema, were mitigated by adding the SGLT2 inhibitor empagliflozin while preserving lanifibranor's metabolic benefit. Investigators in NATiV3 may use diuretics or SGLT2 inhibitors to manage fluid retention, although no formal management algorithm is required by the protocol.
  • Strengthened Balance Sheet and Capital StructureAs of June 30, 2026, Inventiva had EUR 233.9 million of combined cash equivalents and short-term deposits. The company bought back approximately 60% of the EIB warrants with anti-dilution protection for EUR 50 million, repaid EUR 63 million of EIB loans, canceled the remaining EIB warrants with anti-dilution protection, and issued new EIB warrants.
  • Additional Financing SecuredInventiva secured new debt financing of up to EUR 130 million in three committed tranches, subject to conditions, with an initial drawdown of two tranches totaling EUR 75 million gross, plus an additional uncommitted tranche of up to EUR 20 million. The company also completed an underwritten public offering of American depositary shares that generated EUR 103 million in gross proceeds.
  • Cash Runway Covers Key Near-Term MilestonesBased on current financing assumptions, existing resources, and completed financing transactions, the company expects cash runway through the end of the second quarter of 2027, covering the NATiV3 top-line readout and potential NDA filing. Assuming full exercise of Tranche 3 warrants following a positive top-line result and successful completion of Tranche C of the debt financing, runway would extend to the start of the first quarter of 2028.
  • Development Expenses Held FlatR&D expenses were EUR 46.2 million in the first half of 2026, brought in line with the prior year while reflecting continued clinical development of lanifibranor in MASH.
  • Expansion Opportunity in Advanced Liver DiseaseInventiva plans to initiate a confirmatory clinical outcomes trial in compensated advanced chronic liver disease with clinically significant portal hypertension, a population the company described as having no approved disease-modifying therapy. The exploratory NATiV3 cohort is expected to include approximately 75 to 100 cirrhotic patients exposed to lanifibranor for at least 18 months, potentially extending to four years through the active treatment extension.

DE:6IV Earnings History

DE:6IV earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 31, 20272026 (Q4)-0.29--0.93――
Sep 28, 20262026 (Q2)-0.33-0.18-1.3887.16% (+1.20)
Mar 30, 20262025 (Q4)-0.24-0.93-1.6844.88% (+0.75)
Sep 29, 20252025 (Q2)-0.55-1.38-0.81-70.67% (-0.57)
Mar 26, 20252024 (Q4)-0.54-1.68-0.59-184.75% (-1.09)
Sep 25, 20242024 (Q2)-0.72-0.81-1.3138.32% (+0.50)
Mar 27, 20242023 (Q4)-0.63-0.59-0.26-128.68% (-0.33)
Sep 28, 20232023 (Q2)-0.80-1.31-0.72-81.94% (-0.59)
Mar 29, 20232022 (Q4)-0.09-0.26-0.7264.41% (+0.47)
Sep 22, 20222022 (Q2)-0.76-0.72-0.6-20.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed